SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
abortion
Supreme Court Temporarily Extends Abortion Pill Access, But 'Care Is Still Under Attack Every Day'
"Mifepristone is safe and effective, and women should be able to get abortion medication through the mail or telehealth if they need," said Sen. Patty Murray.
May 11, 2026
Defenders of reproductive rights, including key Democrats in Congress, reiterated the safety of mifepristone on Monday after the US Supreme Court temporarily extended access to the medication—commonly used in abortion and miscarriage care—by mail while the justices review a ruling from a notoriously right-wing appellate court.
The US Court of Appeals for the 5th Circuit blocked a federal rule allowing mifepristone to be dispensed by mail at the beginning of the month. Drugmakers quickly appealed to the high court, where Justice Samuel Alito, who is part of the right-wing supermajority, issued a one-week stay to give himself and colleagues time to review the case.
As Alito's initial Monday evening deadline approached, he extended the stay until 5:00 pm ET on Thursday. The move means that "for now, mifepristone is still available via telehealth, mail order, and pharmacy while the case proceeds," noted the Democratic Women's Caucus in the US House of Representatives.
However, pro-choice advocates and policymakers are still sounding the alarm and arguing that, as the caucus put it in a social media post, "reproductive freedom should not depend on emergency rulings or political attacks."
Senate Minority Leader Chuck Schumer (D-NY) said in a statement that "mifepristone has been safe, effective, and trusted for decades. Today's order keeps access in place for now, but it's not cause for celebration—it's a reminder that basic reproductive care is still under attack every day. Anti-abortion extremists are trying to use the courts to roll back access to medication abortion nationwide, and Senate Dems will keep fighting to protect women's freedom to make their own healthcare decisions."
Sen. Patty Murray (D-Wash.) similarly wrote on social media: "Another extension, but this shouldn't be complicated. Mifepristone is safe and effective, and women should be able to get abortion medication through the mail or telehealth if they need. Extremist judges shouldn't get to decide how women get healthcare."
This case traces back to early 2023, when the Biden administration's Food and Drug Administration permanently lifted mifepristone's in-person dispensing requirement, just months after the Supreme Court's right-wing supermajority overturned Roe v. Wade. Louisiana, which has among the most restrictive abortion policies in the country, sued over the FDA's policy change.
Medication abortions account for the majority of abortions provided in the United States, and those patients generally take both mifepristone and another drug, misoprostol. Demand for abortion pills by mail increased after Roe's reversal, as advocates of forced pregnancy policies in Republican-controlled states ramped up attacks on reproductive freedom.
"With the Supreme Court punting a decision on access to mifepristone—a safe, effective medication used in abortion care—until later this week, patients and providers are left facing continued uncertainty," said Rachel Fey, interim co-CEO of Power to Decide. "Wondering day by day whether you'll have access to an essential medication is not practical, and the confusion only deepens the barriers people already face when seeking abortion care."
"Access to mifepristone should be based on scientific evidence, not ideology," Fey declared. "We urge the Supreme Court to follow that science and maintain current telehealth access to mifepristone—not just for a few days at a time, but permanently."
Alito's extensions in recent days are not necessarily signals of where the conservative will ultimately come down. The Associated Press pointed out Monday that "the current dispute is similar to one that reached the court three years ago," when the justices blocked another 5th Circuit ruling "over the dissenting votes of Alito and Justice Clarence Thomas," and then unanimously dismissed that case due to lack of standing, or a legal right to sue.
The battle comes as the Trump administration's FDA is conducting a review of mifepristone that Julia Kaye, senior staff attorney for the ACLU’s Reproductive Freedom Project, has said seems "designed to manufacture an excuse for further restricting medication abortion across the country."
The New York Times noted Monday that US Department of Justice "lawyers have not said in court proceedings or publicly whether they back regulations that allow people to be prescribed the pills through telehealth appointments. Instead, they have asked the lower courts to pause the litigation to give the FDA time to complete a review of the safety of mifepristone, which was first approved in 2000."
Keep ReadingShow Less
Access to Abortion Pill by Mail Restored—For Now—During US Supreme Court Review
"While this is a positive short-term development, no one can rest easy when our ability to get this safe, effective medication for abortion and miscarriage care still hangs in the balance," stressed an ACLU attorney.
May 04, 2026
The US Supreme Court on Monday temporarily restored access to mifepristone, a medication commonly used for abortion and early miscarriage care, through the mail while the justices review a decision requiring it to be dispensed in person by a medical provider.
Justice Samuel Alito, who is part of the high court's right-wing supermajority, oversees the US Court of Appeals for the 5th Circuit. He issued a one-week stay for the appellate court's Friday dispensing decision, which critics had condemned as "sweeping and dangerous."
"This is not particularly surprising from Alito. He's the circuit justice here, acting—in essence—until the full court can act," explained Law Dork's Chris Geidner. He noted that both Alito and Justice Clarence Thomas, another right-winger, "have issued administrative stays in the past until the full court can rule in similar circumstances, regardless of their ultimate votes on the matters."
The drug companies Danco Laboratories, which makes the brand-name version of mifepristone, Mifeprex, and GenBioPro, which makes the generic pill, asked the country's top court to intervene following Friday's ruling, which threatened patients nationwide.
"Even this Supreme Court can see that this 5th Circuit decision is reckless," declared Alexis McGill Johnson, president and CEO of Planned Parenthood Action Fund, on Monday. "While mifepristone access returns to where it was on Friday morning, the whiplash and chaos that patients and providers are navigating have already had real consequences for real people's lives and futures."
Brittany Fonteno, president and CEO of the National Abortion Federation, similarly highlighted how "this back-and-forth has created confusion and chaos," but welcomed that the high court's "decision provides critical, if temporary, relief for patients and providers and ensures that people can continue to access this essential medication through telehealth while the court considers the case."
"The lower court's ruling disregards the well-established safety and efficacy of the use of mifepristone via telehealth, and any future restriction will create medically unnecessary barriers to care for patients across the country," Fonteno added. "Mifepristone has been safely used for more than 25 years, and is essential to abortion care and miscarriage management in the United States. For many patients, especially those in rural areas or facing financial and logistical barriers, access to telehealth is a critical component of holistic reproductive healthcare."
Since the Supreme Court reversed Roe v. Wade in June 2022, the anti-choice movement and right-wing politicians have ramped up attacks on reproductive freedom at the state level. Meanwhile, the Biden administration's Food and Drug Administration (FDA) permanently lifted mifepristone's in-person dispensing requirement in early 2023, allowing doctors in pro-choice states to serve patients across the country via telehealth and the mail, regardless of local laws.
Louisiana responded to the eased restrictions on mifepristone—which is generally taken with another drug, misoprostol, for abortions—by suing, which led to the battle that has now reached the Supreme Court. Prior to Friday's decision by the infamously far-right 5th Circuit, a district judge in the state paused the case due to what the ACLU on Monday called "a sham FDA review announced by the Trump administration," which is ongoing.
"While this is a positive short-term development, no one can rest easy when our ability to get this safe, effective medication for abortion and miscarriage care still hangs in the balance," Julia Kaye, senior staff attorney for the ACLU's Reproductive Freedom Project, stressed Monday. "The Supreme Court needs to put an end to this baseless attack on our reproductive freedom, once and for all."
This article has been updated with comment from the National Abortion Federation.
Keep ReadingShow Less
'Sweeping and Dangerous': US Appeals Court Blocks Mailing of Abortion Pills
The "politically driven" ruling, warned one campaigner, "overrides medical expertise and years of research, and threatens to upend how abortion care is delivered nationwide."
May 01, 2026
Rights advocates swiftly sounded the alarm on Friday after the infamously far-right US Court of Appeals for the 5th Circuit temporarily blocked a federal rule allowing mifepristone to be dispensed by mail, dramatically curtailing access to the medication—commonly used for abortion and early miscarriage care—nationwide, particularly in states with policies hostile to reproductive freedom.
Just months after the US Supreme Court's right-wing supermajority reversed Roe v. Wade, the Food and Drug Administration permanently lifted mifepristone's in-person dispensing requirement in early 2023, under then-President Joe Biden. Louisiana—which has among the nation's most restrictive abortion policies—challenged the FDA's move.
A federal judge in Louisiana paused that lawsuit last month while President Donald Trump's administration conducts an FDA review that seems "designed to manufacture an excuse for further restricting medication abortion across the country," as Julia Kaye, senior staff attorney for the ACLU's Reproductive Freedom Project, warned at the time.
After a panel from the appellate court overturned that decision and revived the in-person dispensing rule on Friday, Kaye declared that "anti-abortion politicians have just made it much harder for people everywhere in the country to get a medication that abortion and miscarriage patients have been safely using for more than 25 years."
"Louisiana's legal attack on mifepristone shamelessly packaged lies and propaganda as an excuse to restrict abortion—and the 5th Circuit rubber-stamped it," she continued. "This decision defies clear science and settled law and advances an anti-abortion agenda that is deeply unpopular with the American people. For countless people, especially those who live in rural areas, face intimate partner violence, or live with disabilities, losing a telemedicine option will mean losing access to this vital medication altogether."
Brittany Fonteno, president and CEO of the National Abortion Federation (NAF), similarly stressed that "this ruling is a sweeping and dangerous rollback that disregards the well-established safety and efficacy of the use of mifepristone via telehealth, and will create immediate, medically unnecessary barriers to care for patients across the country."
"Make no mistake: This ruling is not grounded in science or patient safety," she said. "It is a politically driven decision that overrides medical expertise and years of research, and threatens to upend how abortion care is delivered nationwide. Through this litigation, Louisiana seeks to impose its cruel abortion ban across the nation—including in states with legal protections for abortion—and today the court has taken an extreme step toward that end."
While pledging that "NAF and our allies will continue to advocate to restore full access to medication abortion," Fonteno reminded patients that mifepristone "remains available in doctors' offices, clinics, and hospitals."
Terrific thread. I’ll just add:1. I think there’s a good chance the Supreme Court will stay this decision, allowing providers to keep mailing mifepristone for the time being.2. The Trump administration didn’t want this! Its plan was to wait until after the midterms to crack down on mifepristone.
[image or embed]
— Mark Joseph Stern (@mjsdc.bsky.social) May 1, 2026 at 6:52 PM
After Roe's reversal, the anti-choice movement and its allies in elected offices ramped up efforts to impose state-level restrictions on reproductive healthcare. A significant majority of abortions in the United States involve a two-drug regimen of mifepristone and misoprostol, and a quarter of those patients receive care via telemedicine.
"Telehealth has been the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned," said Nancy Northup, president and CEO of the Center for Reproductive Rights, which joined over 100 other reproductive health, justice, and rights groups, including the ACLU and NAF, that filed an amicus brief in this case.
"This isn't about science—it's about making abortion as difficult, expensive, and unreachable as possible," Northup added. "Telehealth has transformed healthcare. Selectively stripping that away from abortion patients is a political blockade."
The drug companies Danco Laboratories, which makes the brand-name version of mifepristone, Mifeprex, and GenBioPro, which makes the generic, have intervened in Louisiana v. FDA. GenBioPro is represented by the law firm Arnold & Porter and Democracy Forward, whose president and CEO, Skye Perryman, declared Friday that "this is the anti-abortion extremists' playbook in action once again: Weaponize the courts to serve their political interests, ignore decades of scientific evidence proving mifepristone’s safety, and put women directly in harm's way."
"Even as this assault defies the will of the overwhelming majority of the American public, these ideologically extreme politicians and organizations are determined to impose a narrow, autocratic agenda—no matter the cost," she continued, emphasizing that "our fight is not over."
This is a ruling purporting to halt telehealth prescriptions of mifepristone NATIONWIDE. Louisiana asked the Fifth Circuit for a decision by Monday, May 11. That they dropped it on a Friday afternoon feels intentional to keep it in effect for longer. Expect emergency appeal to SCOTUS shadow docket
[image or embed]
— Susan Rinkunas (@susanrinkunas.com) May 1, 2026 at 5:35 PM
The effects of the 5th Circuit's decision are expected to be immediate absent a quick intervention from the Supreme Court, and Nourbese Flint, president of All* Above All, warned that "as always, the people most impacted will be Black and brown communities and those already navigating systemic barriers to care."
Serra Sippel, executive director of the Brigid Alliance, a national abortion support group that helps coordinate and fund travel, said that "we expect to see an immediate increase in patients forced to travel hundreds or even thousands of miles for care. That includes many who are later in pregnancy—when care is more complex and more expensive."
"Over the past several years, we've seen a dramatic rise in abortion travel and a growing reliance on practical support networks like ours, particularly in states where patients already travel long distances for care," Sippel noted. "We will continue to monitor the impact of this ruling and are committed to ensuring abortion patients who need to travel can safely get to the care they need, regardless of where they live."
Keep ReadingShow Less
Most Popular